Ultralife ( (ULBI) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ultralife Corporation has filed a Form 12b-25, announcing a delay in its Annual Report on Form 10-K (Yearly Report) for the year ended December 31, 2025. The company stressed that this late filing notice concerns only the Form 10-K (Yearly Report) and not any other periodic reports.
The main reason for the delay is additional time needed by Ultralife’s independent auditors to complete internal documentation and their review process. This work is required to finalize the audit of both the company’s financial statements and its internal controls over financial reporting.
Ultralife has stated that it expects to file the Form 10-K (Yearly Report) within the 15-day extension window allowed under SEC rules, and no later than March 31, 2026. Investors should view this as a short administrative delay rather than a sign of a prolonged reporting problem, based on the company’s current guidance.
Management emphasized that the delay is not due to any disagreement with the auditors over accounting principles, disclosure, or audit scope. The company also indicated that all other required SEC reports over the past 12 months have been filed on time, supporting its overall compliance track record.
Ultralife does not anticipate any significant change in operating results versus the prior year to be reflected in the upcoming earnings statements. Management also does not expect material changes from the financial information it furnished in an earlier Form 8-K, while reminding investors that these expectations are forward-looking and subject to change.
The company says its independent auditors have provided a supporting statement as required, underscoring ongoing work to complete the audit properly. The notification was signed on March 16, 2026, by Chief Financial Officer and Treasurer Philip A. Fain, signaling continued executive oversight of the filing process and broader compliance efforts.
The most recent analyst rating on (ULBI) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Ultralife stock, see the ULBI Stock Forecast page.
Spark’s Take on ULBI Stock
According to Spark, TipRanks’ AI Analyst, ULBI is a Neutral.
The score is driven primarily by moderate financial performance (low leverage but weaker margins and declining free cash flow) and strong technical momentum (price above major moving averages with positive MACD). These positives are offset by a stretched valuation (high P/E) and a mixed earnings update where revenue and backlog growth were tempered by losses and margin pressure.
To see Spark’s full report on ULBI stock, click here.
More about Ultralife
Average Trading Volume: 47,261
Technical Sentiment Signal: Buy
Current Market Cap: $116.7M
See more insights into ULBI stock on TipRanks’ Stock Analysis page.